Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 22 October 2021 | By Jeff Craven 

COVID-19 therapeutics tracker

More than a year into the pandemic, only a handful of repurposed therapeutics have been approved to treat COVID-19: dexamethasone in the UK and Japan; Avigan (favilavir) in China, Italy and Russia; and Veklury (remdesivir) in the US, UK and Japan.
Regulators around the world have allowed a handful of treatments to be used on an emergency-use basis including Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology's Xevudy (sotrovimab); Roche's Actemra; Celltrion's Regkirona; and convalescent plasma. 
Several large international trials are underway. The largest, SOLIDARITY, is led by the World Health Organization (WHO). More than 100 countries have joined SOLIDARITY to evaluate high-profile treatment candidates for COVID-19.

This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at
Updated 22 October to include new information on molnupiravir, tixagevimab and cilgavimab, BRII-196/BRII-198, heparin, casirivimab and imdevimab, Veklury, dexamethasone, and colchicine




© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.